Trial for metastatic lung cancer after PD-1 or PD-L1 treatment failure
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares ONC-392 versus docetaxel (a standard chemotherapy) in metastatic squamous non-small cell lung cancer that has grown again after PD-1/PD-L1 immunotherapy. It’s testing whether ONC-392 can control the cancer better or more safely after prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18+) and able to sign consent
- Your lung cancer is confirmed as metastatic squamous NSCLC (with spread to lymph nodes or other organs)
- Your scans show the cancer grew after PD-1/PD-L1 immunotherapy plus platinum chemotherapy, and you’ve also had at least 2 rounds of platinum chemotherapy
- You have at least one measurable tumor spot on a scan and you’re not too limited in daily activities (ECOG 0–1)
- Your blood counts and organ health are good enough, and your expected survival is at least 3 months
- You don’t have certain mutations (EGFR, ALK, ROS1, HER2, MET, BRAF, RET, or NTRK); KRAS is allowed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This Phase 3 trial compares AL2846 pills plus TQB2450 injections against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer. You may qualify if your cancer has progressed after platinum chemotherapy and immunotherapy, and if certain tumor genetic tests are negative.
This trial tests an investigational drug (telisotuzumab vedotin) against the standard chemotherapy docetaxel in people with a certain type of non-squamous lung cancer that has high levels of a protein called c-Met. It may offer a new treatment option for those whose cancer has progressed after initial therapy.
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
This trial tests a new drug called SYS6010 against a standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer that does not have an EGFR mutation and has stopped responding to previous treatments. The goal is to see which treatment works better.
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.